s
Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
06-02-2025, 13:02
SHANGHAI, Feb. 6, 2025 /PRNewswire/ — Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy’s Laboratories SA, wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”) for the company’s […] L'articolo Henlius and Dr. Reddy’s Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. proviene da La Ragione.
CONTINUA A LEGGERE
26
0
0
Guarda anche
La Ragione
15:19
Nuoto: Italia argento nella staffetta 4×100 sl maschile
La Ragione
14:43
Incidenti: scontro tra auto sulla A4, 4 vittime e un ferito
La Ragione
13:45